Recombinant Anti-HER3 x Anti-IGF1R Bispecific Antibody (VHH-IgG) (BSSG-406)

Recombinant Anti-HER3 x Anti-IGF1R Bispecific Antibody (VHH-IgG) is formed by an IgG and two VHH fragments. The VHHs from an anti-IGF1R antibody variable domain are respectively connected to the N terminus of the anti-HER3 IgG heavy chains or light chains to form VHH-(H)IgG or VHH-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Pancreatic cancer; Hepatocellular carcinoma (HCC) therapy.

Datasheet INQUIRY

Specifications

Targets

HER3 & IGF1R

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Pancreatic cancer; Hepatocellular carcinoma (HCC)

Targets

Target 1

HER3

Gene ID

2065

UniProt ID

P21860

Alternative Names

ERBB3; erb-b2 receptor tyrosine kinase 3; HER3; LCCS2; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; c-erbB-3; p180-ErbB3; p45-sErbB3; p85-sErbB3; receptor tyrosine-protein kinase erbB-3; proto-oncogene-like protein c-ErbB-3; human epidermal growth factor receptor 3; tyrosine kinase-type cell surface receptor HER3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3

Target 2

IGF1R

Gene ID

3480

UniProt ID

P08069

Alternative Names

IGF1R; insulin-like growth factor 1 receptor; IGFR; CD221; IGFIR; JTK13; IGF-I receptor; soluble IGF1R variant 1; soluble IGF1R variant 2; insulin-like growth factor I receptor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-HER3 x Anti-IGF1R Bispecific Antibody (VHH-IgG) (BSSG-406). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-HER3 x Anti-IGF1R Bispecific Antibody (VHH-IgG) (CAT#: BSSG-406)

Specifications

Targets

Customer Reviews and Q&As